QT Imaging Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on December 11, 2024, by QT Imaging Holdings, Inc. (QTI), a Delaware corporation and emerging growth company. The filing details the entry into an Amended and Restated Distribution Agreement with NXC Imaging, Inc. (NXC), a wholly-owned subsidiary of Canon Medical Systems USA, Inc.
Key Financial Metrics
The filing text does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The document focuses exclusively on the terms of a material commercial agreement.
Material Changes and Agreement Terms
The Amended and Restated Distribution Agreement modifies the original June 2024 agreement and the October 2024 First Amendment. Key changes include:
- Condition Precedent: NXC's status as the exclusive reseller in the U.S. is now contingent upon Canon Medical Systems Corporation entering into a Manufacturing Agreement by December 30, 2024.
- Minimum Order Quantities (MOQs): NXC must provide quarterly forecasts and purchase orders meeting specific MOQs for 2025 and 2026 (detailed in Exhibit C). If NXC fails to meet these orders, QT Imaging may invoice NXC for the difference. These MOQs are non-binding only if QT Imaging cannot fulfill the required volumes due to the absence of the Manufacturing Agreement.
- Pricing and Markup: The agreement removes the previous cap on NXC's resale markup, allowing NXC to set resale prices at its sole discretion. Purchase prices are based on a schedule in Exhibit B, subject to change with 60 days' notice.
- Payment Terms: NXC must pay invoices within 30 days of equipment shipment.
- Service and Warranty: QT Imaging is obligated to provide technical support and spare parts for at least five years post-installation. The requirement for customers to have a qualified breast radiologist was removed. Limited warranties apply for 15 months (equipment) and 12 months (spare parts) from shipment or installation acceptance.
- Non-Solicitation: A three-year non-solicitation clause applies to NXC's business relationships and employees, with exceptions for QT Imaging's necessary engagement with end customers.
- Term Extension: The agreement term is extended from December 31, 2025, to December 31, 2026.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary on future earnings. The primary risk identified is the conditionality of the exclusive reseller arrangement on the execution of a Manufacturing Agreement with Canon Medical Systems Corporation by December 30, 2024. Failure to secure this agreement may impact the enforceability of Minimum Order Quantities.
Investor Verification Checklist
- Verify whether the Manufacturing Agreement with Canon Medical Systems Corporation was executed by the December 30, 2024 deadline.
- Review Exhibit C of the attached Amended Distribution Agreement to understand the specific Minimum Order Quantities for 2025 and 2026.
- Assess the financial impact of the removed resale markup cap on NXC's pricing strategy and QT Imaging's potential revenue per unit.
- Monitor future filings for any updates regarding the fulfillment of MOQs or potential invoicing for shortfalls.